---
title: "Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301601991.md"
description: "On Monday, Bristol Myers Squibb achieved success in two Phase 3 trials related to lung disease and cancer, leading to a significant increase in their stock value. Meanwhile, a major competitor experienced a sharp decline in their stock price. This development underscores Bristol Myers Squibb's strong performance in the pharmaceutical sector and its potential to impact the market."
datetime: "2026-10-12T14:25:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301601991.md)
  - [en](https://longbridge.com/en/news/301601991.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301601991.md)
generator: "portal-rs"
---

# Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One

On Monday, Bristol Myers Squibb achieved success in two Phase 3 trials related to lung disease and cancer, leading to a significant increase in their stock value. Meanwhile, a major competitor experienced a sharp decline in their stock price. This development underscores Bristol Myers Squibb's strong performance in the pharmaceutical sector and its potential to impact the market.

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause](https://longbridge.com/en/news/302909326.md)
- [BUZZ-Bristol Myers rises on positive trial results for cancer and lung disease drugs](https://longbridge.com/en/news/301590676.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [Bristol Myers Squibb says ZENBEXUS combo cuts multiple myeloma progression risk 51% in Phase 3 EXCALIBER-RRMM trial](https://longbridge.com/en/news/301263394.md)
- [BUZZ-Contineum tumbles as Bristol's partial trial win raises dose doubts](https://longbridge.com/en/news/301592637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**